Oligodendroglia and neurotrophic factors in neurodegeneration

Neuroscience Bulletin

Volumn 29, Issue 2, 2013, Pages 216-228

  Bankston, Andrew N ^a   Mandler, Mariana D ^a   Feng, Yue ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

myelination; neurodegenerative diseases; neuron glial communication; neurotrophic factors; oligodendroglia

Indexed keywords

MYELIN; NEUROTROPHIC FACTOR;

ALZHEIMER DISEASE; AXONAL INJURY; CELL COMMUNICATION; CELL INTERACTION; CELL LOSS; CELL METABOLISM; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MYELIN SHEATH; MYELINATION; NERVE POTENTIAL; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW;

ACTION POTENTIALS; ANIMALS; CELL COMMUNICATION; HUMANS; MYELIN SHEATH; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEURONS; OLIGODENDROGLIA;

EID: 84877872994     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-013-1321-3     Document Type: Review

References (134)

1. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012, 8: 647-656.
2. Matute C, Alberdi E, Ibarretxe G, Sánchez-Gómez MaV. Excitotoxicity in glial cells. Eur J Pharmacol 2002, 447: 239-246.
3. You Y, Bai H, Wang C, Chen LW, Liu B, Zhang H, et al. Myelin damage of hippocampus and cerebral cortex in rat pentylenetetrazol model. Brain Res 2011, 1381: 208-216.
4. Hobson GM, Garbern JY. Pelizaeus-Merzbacher disease, Pelizaeus- Merzbacher-like disease 1, and related hypomyelinating disorders. Semin Neurol 2012, 32: 62-67.
5. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J Psychiatr Res 2010, 44: 149-156.
6. Schmitt A, Hasan A, Gruber O, Falkai P. Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 2011, 261: 150-154.
7. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008, 31: 535-561.
8. Byravan S, Foster LM, Phan T, Verity AN, Campagnoni AT. Murine oligodendroglial cells express nerve growth factor. Proc Natl Acad Sci U S A 1994, 91: 8812-8816.
9. Dai X, Lercher LD, Clinton PM, Du Y, Livingston DL, Vieira C, et al. The trophic role of oligodendrocytes in the basal forebrain. J Neurosci 2003, 23: 5846-5853.
10. Dai X, Qu P, Dreyfus CF. Neuronal signals regulate neurotrophin expression in oligodendrocytes of the basal forebrain. Glia 2001, 34: 234-239.
11. Du Y, Dreyfus CF. Oligodendrocytes as providers of growth factors. J Neurosci Res 2002, 68: 647-654.
12. Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009, 29: 43-68.
13. Wilkins A, Majed H, Layfield R, Compston A, Chandran S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J Neurosci 2003, 23: 4967-4974.
14. Wilkins A, Chandran S, Compston A. A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Glia 2001, 36: 48-57.
15. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002, 8: 620-624.
16. Villoslada P, Genain CP. Role of nerve growth factor and other trophic factors in brain inflammation. Prog Brain Res 2004, 146: 403-414.
17. VonDran MW, Singh H, Honeywell JZ, Dreyfus CF. Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion. J Neurosci 2011, 31: 14182-14190.
18. Ishibashi T, Lee PR, Baba H, Fields RD. Leukemia inhibitory factor regulates the timing of oligodendrocyte development and myelination in the postnatal optic nerve. J Neurosci Res 2009, 87: 3343-3355.
19. Spiegel I, Peles E. A new player in CNS myelination. Neuron 2006, 49: 777-778.
20. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487: 443-448.
21. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338: 278-285.
22. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998, 121: 1469-1477.
23. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46: 296-304.
24. Nave KA. Myelination and support of axonal integrity by glia. Nature 2010, 468: 244-252.
25. Wilkins A, Kondo Y, Song J, Liu S, Compston A, Black JA, et al. Slowly progressive axonal degeneration in a rat model of chronic, nonimmune-mediated demyelination. J Neuropathol Exp Neurol 2010, 69: 1256-1269.
26. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134: 1914-1924.
27. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132: 1161-1174.
28. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008, 131: 1722-1735.
29. Campbell GR, Ohno N, Turnbull DM, Mahad DJ. Mitochondrial changes within axons in multiple sclerosis: an update. Curr Opin Neurol 2012, 25: 221-230.
30. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132: 1175-1189.
31. Stys PK, Waxman SG, Ransom BR. Na+-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann Neurol 1991, 30: 375-380.
32. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009, 8: 280-291.
33. Worku Hassen G, Feliberti J, Kesner L, Stracher A, Mokhtarian F. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res 2008, 1236: 206-215.
34. Sathornsumetee S, McGavern DB, Ure DR, Rodriguez M. Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis. Am J Pathol 2000, 157: 1365-1376.
35. Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008, 9: 839-855.
36. Crawford DK, Mangiardi M, Xia X, Lopez-Valdes HE, Tiwari-Woodruff SK. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience 2009, 164: 1407-1421.
37. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001, 11: 107-116.
38. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998, 280: 1610-1613.
39. Yin X, Crawford TO, Griffin JW, Tu Ph, Lee VM, Li C, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998, 18: 1953-1962.
40. Yang LJ, Zeller CB, Shaper NL, Kiso M, Hasegawa A, Shapiro RE, et al. Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc Natl Acad Sci U S A 1996, 93: 814-818.
41. Pan B, Fromholt SE, Hess EJ, Crawford TO, Griffin JW, Sheikh KA, et al. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: Neuropathology and behavioral deficits in single- and double-null mice. Exp Neurol 2005, 195: 208-217.
42. Poliak S, Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 2003, 4: 968-980.
43. Zhu H, Zhao L, Wang E, Dimova N, Liu G, Feng Y, et al. The QKI-PLP pathway controls SIRT2 abundance in CNS myelin. Glia 2012, 60: 69-82.
44. Werner HB, Kuhlmann K, Shen S, Uecker M, Schardt A, Dimova K, et al. Proteolipid protein is required for transport of Sirtuin 2 into CNS myelin. J Neurosci 2007, 27: 7717-7730.
45. Li W, Zhang B, Tang J, Cao Q, Wu Y, Wu C, et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through Deacetylating α-tubulin. J Neurosci 2007, 27: 2606-2616.
46. Oluich LJ, Stratton JA, Xing YL, Ng SW, Cate HS, Sah P, et al. Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. J Neurosci 2012, 32: 8317-8330.
47. Gelfo F, Tirassa P, De Bartolo P, Caltagirone C, Petrosini L, Angelucci F. Brain and serum levels of nerve growth factor in a rat model of Alzheimer's disease. J Alzheimer's Dis 2011, 25: 213-217.
48. Lorigados Pedre L, Pavon Fuentes N, Alvarez Gonzalez L, McRae A, Serrano Sanchez T, Blanco Lescano L, et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res 2002, 952: 122-127.
49. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005, 93: 1412-1421.
50. Tasset I, Sanchez-Lopez F, Aguera E, Fernandez-Bolanos R, Sanchez FM, Cruz-Guerrero A, et al. NGF and nitrosative stress in patients with Huntington's disease. J Neurol Sci 2012, 315: 133-136.
51. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev. Neurol 2009, 5: 311-322.
52. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brainderived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002, 132: 180-188.
53. Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, et al. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res 2010, 1333: 64-71.
54. Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci U S A 2008, 105: 13139-13144.
55. Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, Malerba F, et al. Intranasal "painless" human Nerve Growth Factors slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice. PLoS One 2012, 7: e37555.
56. Ebert AD, Beres AJ, Barber AE, Svendsen CN. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol 2008, 209: 213-223.
57. Ebert AD, Barber AE, Heins BM, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 2010, 224: 155-162.
58. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2006, 103: 9345-9350.
59. Althaus HH. Remyelination in multiple sclerosis: a new role for neurotrophins? Prog Brain Res 2004, 146: 415-432.
60. De Santi L, Annunziata P, Sessa E, Bramanti P. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neurol Sci 2009, 287: 17-26.
61. Marriott MP, Emery B, Cate HS, Binder MD, Kemper D, Wu Q, et al. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia 2008, 56: 686-698.
62. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010, 133: 2232-2247.
63. Ebadi M, Bashir RM, Heidrick ML, Hamada FM, Refaey HE, Hamed A, et al. Neurotrophins and their receptors in nerve injury and repair. Neurochem Int 1997, 30: 347-374.
64. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010, 133: 2248-2263.
65. Melli G, Hoke A. Canadian Association of Neurosciences review: regulation of myelination by trophic factors and neuron-glial signaling. Can J Neurol Sci 2007, 34: 288-295.
66. Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010, 30: 6236-6246.
67. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 2002, 8: 613-619.
68. Knapp PE, Adams MH. Epidermal growth factor promotes oligodendrocyte process formation and regrowth after injury. Exp Cell Res 2004, 296: 135-144.
69. Lee DH, Geyer E, Flach AC, Jung K, Gold R, Flügel A, et al. Central nervous system rather than immune cellderived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol 2012, 123: 247-258.
70. Tabakman R, Lecht S, Sephanova S, Arien-Zakay H, Lazarovici P. Interactions between the cells of the immune and nervous system: neurotrophins as neuroprotection mediators in CNS injury. Prog Brain Res 2004, 146: 387-401.
71. Gudi V, Skuljec J, Yildiz O, Frichert K, Skripuletz T, Moharregh-Khiabani D, et al. Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS One 2011, 6: e22623.
72. Butzkueven H, Emery B, Cipriani T, Marriott MP, Kilpatrick TJ. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 2006, 53: 696-703.
73. Zhu W, Frost EE, Begum F, Vora P, Au K, Gong Y, et al. The role of dorsal root ganglia activation and brain-derived neurotrophic factor in multiple sclerosis. J Cell Mol Med 2012, 16: 1856-1865.
74. Laudiero LB, Aloe L, Levi-Montalcini R, Buttinelli C, Schilter D, Gillessen S, et al. Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci Lett 1992, 147: 9-12.
75. Gonzalez-Perez O, Romero-Rodriguez R, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A. Epidermal growth factor induces the progeny of subventricular zone type B cells to migrate and differentiate into oligodendrocytes. Stem Cells 2009, 27: 2032-2043.
76. Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 2007, 10: 990-1002.
77. Baj G, Leone E, Chao MV, Tongiorgi E. Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments. Proc Natl Acad Sci U S A 2011, 108: 16813-16818.
78. Chiaruttini C, Sonego M, Baj G, Simonato M, Tongiorgi E. BDNF mRNA splice variants display activity-dependent targeting to distinct hippocampal laminae. Mol Cell Neurosci 2008, 37: 11-19.
79. Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 2009, 29: 12764-12767.
80. Metsis M, Timmusk T, Arenas E, Persson H. Differential usage of multiple brain-derived neurotrophic factor promoters in the rat brain following neuronal activation. Proc Natl Acad Sci U S A 1993, 90: 8802-8806.
81. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007, 85: 525-535.
82. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, et al. Distinct 3'UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). Proc Natl Acad Sci U S A 2010, 107: 15945-15950.
83. Yamakuni H, Kawaguchi N, Ohtani Y, Nakamura J, Katayama T, Nakagawa T, et al. ATP induces leukemia inhibitory factor mRNA in cultured rat astrocytes. J Neuroimmunol 2002, 129: 43-50.
84. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes promote myelination in response to electrical impulses. Neuron 2006, 49: 823-832.
85. Deverman BE, Patterson PH. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J Neurosci 2012, 32: 2100-2109.
86. Marmur R, Kessler JA, Zhu G, Gokhan S, Mehler MF. Differentiation of oligodendroglial progenitors derived from cortical multipotent cells requires extrinsic signals including activation of gp130/LIFbeta receptors. J Neurosci 1998, 18: 9800-9811.
87. Lee DA, Zurawel RH, Windebank AJ. Ciliary neurotrophic factor expression in Schwann cells is induced by axonal contact. J Neurochem 1995, 65: 564-568.
88. Stockli KA, Lillien LE, Naher-Noe M, Breitfeld G, Hughes RA, Raff MC, et al. Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J Cell Biol 1991, 115: 447-459.
89. Rivera FJ, Kandasamy M, Couillard-Despres S, Caioni M, Sanchez R, Huber C, et al. Oligodendrogenesis of adult neural progenitors: differential effects of ciliary neurotrophic factor and mesenchymal stem cell derived factors. J Neurochem 2008, 107: 832-843.
90. Cao Q, He Q, Wang Y, Cheng X, Howard RM, Zhang Y, et al. Transplantation of ciliary neurotrophic factor-expressing adult oligodendrocyte precursor cells promotes remyelination and functional recovery after spinal cord injury. J Neurosci 2010, 30: 2989-3001.
91. Kelleher MO, Myles LM, Al-Abri RK, Glasby MA. The use of ciliary neurotrophic factor to promote recovery after peripheral nerve injury by delivering it at the site of the cell body. Acta Neurochir 2006, 148: 55-60; discussion 60-51.
92. Kang SS, Keasey MP, Cai J, Hagg T. Loss of neuronastroglial interaction rapidly induces protective CNTF expression after stroke in mice. J Neurosci 2012, 32: 9277-9287.
93. Gold BT, Johnson NF, Powell DK, Smith CD. White matter integrity and vulnerability to Alzheimer's disease: Preliminary findings and future directions. Biochim Biophys Acta 2012, 1822: 416-422.
94. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006, 21: 1317-1325.
95. Di Paola M, Luders E, Cherubini A, Sanchez-Castaneda C, Thompson PM, Toga AW, et al. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. Cereb Cortex 2012, 22: 2858-2866.
96. Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol 2011, 7: 229-236.
97. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118: 5-36.
98. Zheng Z, Diamond MI. Huntington Disease and the huntingtin protein. Prog in Mol Biol Transl Sci 2012, 107: 189-214.
99. Jellinger KA. Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. Mov Disord 2012, 27: 8-30.
100. Alberch J, Perez-Navarro E, Canals JM. Neurotrophic factors in Huntington's disease. Prog Brain Res 2004, 146: 195-229.
101. Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 2004, 8: 391-399.
102. Lu PH, Lee GJ, Tishler TA, Meghpara M, Thompson PM, Bartzokis G. Myelin breakdown mediates age-related slowing in cognitive processing speed in healthy elderly men. Brain Cogn 2013, 81: 131-138.
103. Roth AD, Ramirez G, Alarcon R, Von Benhardi R. Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation. Biol Res 2005, 38: 381-387.
104. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG. Amyloid [beta]-peptide-induced corpus callosum damage and glial activation in vivo. NeuroReport 2003, 14: 1429-1433.
105. Desai MK, Guercio BJ, Narrow WC, Bowers WJ. An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia 2011, 59: 627-640.
106. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009, 57: 54-65.
107. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 2010, 177: 1422-1435.
108. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005, 171: 1001-1012.
109. Hsiao H-Y, Chern Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol Neurobiol 2010, 41: 248-255.
110. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 2009, 106: 22480-22485.
111. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006, 47: 215-222.
112. Beglinger LJ, Nopoulos PC, Jorge RE, Langbehn DR, Mikos AE, Moser DJ, et al. White matter volume and cognitive dysfunction in early Huntington's disease. Cogn Behav Neurol 2005, 18: 102-107.
113. Bartzokis G, Lu P, Tishler T, Fong S, Oluwadara B, Finn JP, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007, 32: 1655-1664.
114. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol 1991, 50: 729-742.
115. Gómez-Tortosa E, MacDonald ME, Friend JC, Taylor SAM, Weiler LJ, Cupples LA, et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 2001, 49: 29-34.
116. Halliday GM, Stevens CH. Glia: Initiators and progressors of pathology in Parkinson's disease. Mov Disord 2011, 26: 6-17.
117. Arai T, Uéda K, Ikeda K, Akiyama H, Haga C, Kondo H, et al. Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein. Neurosci Lett 1999, 259: 83-86.
118. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 2000, 99: 14-20.
119. Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004, 25: 19-23.
120. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009, 201: 1-119.
121. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992, 84: 100-104.
122. Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012, 38: 4-24.
123. Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009, 8: 1172-1178.
124. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: A primary oligodendrogliopathy. Ann Neurol 2008, 64: 239-246.
125. Stefanova N, Schanda K, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Tumor necrosis factor-α-induced cell death in U373 cells overexpressing α-synuclein. J Neurosci Res 2003, 73: 334-340.
126. Riedel M, Goldbaum O, Richter-Landsberg C. α-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J Mol Neurosci 2009, 39: 226-234.
127. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, et al. Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005, 166: 869-876.
128. Hasegawa T, Baba T, Kobayashi M, Konno M, Sugeno N, Kikuchi A, et al. Role of TPPP/p25 on α-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int 2010, 57: 857-866.
129. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, et al. α-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 2009, 284: 10211-10222.
130. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002, 3: 583-588.
131. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, et al. Mouse model of multiple system atrophy alphasynuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45: 847-859.
132. Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: Implications for multiple system atrophy. J Neurosci 2005, 25: 10689-10699.
133. Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010, 30: 6236-6246.
134. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487: 443-448.